A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally
advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
Phase:
Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)